PLAUR and cancer: In preclinical studies, [64Cu]Cu-labeled uPAR-targeting radioligands have been explored in different cancer cell line xenograft models [42, 43], and the correlation between [64Cu]Cu-DOTA-AE105 uptake in tumor and the uPAR expression was established by uPAR ELISA [43].